Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerepro (HSV-TK gene therapy) plus ganciclovir in operable high grade malignant glioma
2004-000464-28Phase 3Completed
- Sponsor
- Ark Therapeutics
- Start
- Nov 2004
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of Ad.TK in malignant glioma (2 arms), sponsored by Ark Therapeutics. Primary endpoint: All-cause mortality. Started Nov 2004; status: completed.
02
Drugs
Ad.TK
03
Conditions
malignant glioma
Beyond the preview
Go deeper on 2004-000464-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000464-28.